- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04102384
Usability and Satisfaction With an Electronic Survey Administration Application in General Population (CePRO)
Panoramica dello studio
Descrizione dettagliata
Patient-reported outcomes (PROs) are vital to understanding the impact of a medical condition and treatment from the participant's perspective. However, the collection of data can be inconsistent in both administration and completion due to the method of delivery. Thus, careful consideration of the data collection mode is needed to ensure the quality of the data. The method of delivery has been shown to have a direct effect on the survey response rates thereby ensuring the validity of the data analyses and results. Previous studies have demonstrated an increase in Web-based survey response rates as compared to paper-based survey response rates. Novel methods of collecting PROs may help to streamline both the process and collection of PROs during clinical trials.
A potential differentiating factor between delivering surveys via smart phone and other electronic modes of delivery is the perceived advantage of being able to conveniently complete survey questionnaires at any time and any location. This could help address certain limitations of the quantitative survey method such as recall bias. Furthermore, the portability, connectivity and ubiquity of smartphones may reduce the amount of training or instructions required for users to complete a survey questionnaire on a smartphone. For researchers, this type of survey delivery method may offer the benefits of a wider target audience and reduce research implementation costs. The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires. The goal of this two-arm randomized controlled pilot is to explore the usability and satisfaction with a novel e-PRO app.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Partners HealthCare
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy participants over the age of 18-65 years as assessed by the Self-Rated Health Measure.
- Fluency in English language to be able to read, understand study procedures and complete surveys administered during the study.
- Willing to travel to the downtown Boston area to participate in up to two study visits.
- Willing to participate in the research study and sign informed consent.
Exclusion Criteria:
- Participants with a "fair" or "poor" rating on the Self-Rated Health Measure.
- Participants with EU citizenship or permanent residency
- Participants with severe cognitive, vision, hearing, or speech problems that may prevent them from answering surveys
- Participants with serious psychiatric conditions (moderate or major depressive disorder that may impair their ability to complete surveys
- Participants with any terminal illness (e.g. cancers)
- Patients with implantable devices, pacemakers or body worn electronic medical devices
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Control Group
Participants will be enrolled for a period of 4 weeks.
At baseline, we will collect demographic information on participants.
During the study, participants will be asked to fill out daily and weekly surveys using an electronically link sent via email.
Additionally, participants will be asked to fill out one survey once a week during the study period.
|
|
|
Sperimentale: Intervention Group
Participants will be enrolled for a period of 4 weeks.
At baseline, we will collect demographic information on participants.
During the study, participants will be asked to fill out daily and weekly surveys using the e-PRO app.
Additionally, participants will be asked to fill out one survey once a week during the study period.
A subgroup of these participants will be asked to complete an additional interview to collect more information on their experiences using the mobile app.
|
The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants.
Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Usability of e-PRO vs. emailed link: survey
Lasso di tempo: At close-out
|
A survey will be administered to compare groups on their experiences with the survey-method administration (Investigator developed survey).
The following components will be taken into account: acceptability-- participant satisfaction with various aspects of the solution (e.g.
content, complexity, comfort, delivery, and credibility).
Adoption-- participants' intention to try; perceived barriers and facilitators for uptake.
Appropriateness-- participant's perceived relevance to need; suitability to daily patient workflow.
Feasibility-- suitability for using daily, weekly etc.
This survey is not a scored survey.
|
At close-out
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Survey response rate e-PRO vs emailed link
Lasso di tempo: At close-out
|
Response rate will be tracked on a weekly basis from the e-PRO system and the REDCap embedded email link to compare response rate between the control and intervention group.
The AAOPR (2006) recommendation for RR formula will be used to calculate the RR.
This is the number of completed surveys (completed and partially completed) divided by the number of completed surveys (completed and partially completed) plus the number of all non-completed surveys (sent to a potential participant but not completed because of incorrect e-mail address, incorrect mailing address, or other reasons).
|
At close-out
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Ramya S Palacholla, MD, MPH, Partners HealthCare
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 2019P002811
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su e-PRO App
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletatoAnemia falciforme | Falce B+ Talassemia | Falce Beta Zero Talassemia | Emoglobina falciforme CStati Uniti
-
Cairo UniversitySconosciuto
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)Completato
-
CytoDyn, Inc.WEP ClinicalA disposizioneTNBC, cancro al seno triplo negativo | TNBC - Cancro al seno triplo negativo | TNBCStati Uniti
-
The University of Hong KongNon ancora reclutamentoSalute digitale | Dolore al ginocchio/artrosiHong Kong
-
Bolton MedicalAttivo, non reclutanteDissezione aortica di tipo BStati Uniti
-
Institute for Human Development and Potential (IHDP)...Attivo, non reclutanteDiabete di tipo 2 | Diabete gestazionale | Comportamenti di stile di vita saniSingapore
-
London School of Hygiene and Tropical MedicineCompletatoNutrizione | Sostenibilità | Tecnologia sanitaria mobile (mHealth)Regno Unito
-
Emory UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completato
-
National Cancer Institute (NCI)ReclutamentoCancro alla prostataStati Uniti